News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Antisoma PLC Announces Positive ASA404 Presentations at American Society of Clinical Oncology
May 30, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON--(Marketwire - May 30, 2008) - Antisoma (LSE: ASM; USOTC:ATSMY) announces today details of two presentations on ASA404 that will be made at the upcoming 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO):
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Events
Europe
MORE ON THIS TOPIC
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
September 30, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
September 29, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Hansa Kidney Transplant Drug Aces Phase III Study, Headed to FDA
September 26, 2025
·
2 min read
·
Tristan Manalac
Job Trends
$100,000 H-1B Fee Leaves Biopharma Grappling With Impact
September 25, 2025
·
6 min read
·
Angela Gabriel
